STING agonist-3
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer[1].
Product Specifications
CAS Number
2138299-29-1
UNSPSC
12352005
Target
STING
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sting-agonist-3.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : 41.67 mg/mL (ultrasonic)
Smiles
O=C(N)C1=CC=C(N(C(NC(C2=CC(C)=NN2CC)=O)=N3)C/C=C/CN4C5=C(N=C4NC(C6=CC(C)=NN6CC)=O)C=C(C(N)=O)C=C5OCCCO)C3=C1
Molecular Formula
C37H42N12O6
Molecular Weight
750.81
References & Citations
[1]Adam Kenneth, et al. Heterocyclic amides useful as protein modulators.patent WO2017175147A1|[2]Ramanjulu JM, Pesiridis GS, Yang J, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity [published correction appears in Nature. 2019 Jun;570 (7761) :E53. doi: 10.1038/s41586-019-1265-5]. Nature. 2018;564 (7736) :439-443.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-61317R-Cy3-TR 20 µL
Complement C4 / C4a Recombinant Antibody, Cy3 Conjugated
Sign In for Pricing
View Details 
